Autolane | $7,400,000 | (Dec 4, 2025)
Curvestone AI | $4,000,000 | (Dec 4, 2025)
Ridley | $6,400,000 | (Dec 4, 2025)
Certified by Founder
Lodge
Delphia Therapeutics
start up
United States
- Cambridge, Massachusetts
- 07/05/2024
- Series A
- $67,000,000
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
- Industry Biotechnology Research
- Website https://www.delphiatx.com/
- LinkedIn https://www.linkedin.com/company/delphia-therapeutics/
Track Titan | $5,000,000 | (Dec 4, 2025)
Curi Bio | $10,000,000 | (Dec 4, 2025)
Unacast | $28,000,000 | (Dec 4, 2025)
Fin | $17,000,000 | (Dec 4, 2025)
Supper | $11,000,000 | (Dec 4, 2025)
Gradium | $70,000,000 | (Dec 4, 2025)
Juniper Biosciences | $40,000,000 | (Dec 4, 2025)
Heven AeroTech | $100,000,000 | (Dec 4, 2025)
PineAI | $25,000,000 | (Dec 4, 2025)